Injection site reaction to teclistamab in a patient with multiple myeloma

Injection site reaction to teclistamab in a patient with multiple myeloma

Saved in:

Bibliographic Details
Main Authors:	Isabel C. Yoon, BS, Ngan Do, MD, Thomas Vazquez, MD, David E. Elder, MD, Katherine T. Steele, MD, Misha Rosenbach, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	JAAD Case Reports
Subjects:	bispecific antibodies bispecific T-cell engagers drug reaction injection site reaction multiple myeloma teclistamab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512624004090
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment
by: Minchuan Zhang, et al.
Published: (2024-11-01)

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service
by: Rakesh Popat, et al.
Published: (2024-12-01)

Proximity‐Unlocked Luminescence by Sequential Enzymatic Reactions from Antibody and Antibody/Aptamer (PULSERAA): A Platform for Detection and Visualization of Virus‐Containing Spots
by: Daimei Miura, et al.
Published: (2024-11-01)

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
by: Charissa Wijnands, et al.
Published: (2025-01-01)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
by: Guido Lancman, et al.
Published: (2024-11-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01)

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
by: Giulio Cassanello, et al.
Published: (2024-12-01)

Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study
by: Christian Herbert Burgmann, et al.
Published: (2024-10-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer
by: Yuankui Zhu, et al.
Published: (2025-02-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
by: Ziping Li, et al.
Published: (2025-01-01)

Non-affinity platform for processing knob-into-hole bispecific antibody
by: Xiaoyang Wang, et al.
Published: (2024-12-01)

A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
by: Qi Song, et al.
Published: (2024-11-01)

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
by: Julia Palecki, et al.
Published: (2024-12-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

The landscape of T-cell engagers for the treatment of follicular lymphoma
by: Alfredo Rivas-Delgado, et al.
Published: (2024-12-01)

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study
by: Jennifer Moore, et al.
Published: (2025-12-01)

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins
by: Eilyn R. Lacy, et al.
Published: (2025-01-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies
by: Olivier Nolan-Stevaux, et al.
Published: (2024-11-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies
by: Shen Luo, et al.
Published: (2024-12-01)

TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models
by: Yang Shi, et al.
Published: (2024-12-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach
by: Punchita Rujirachaivej, et al.
Published: (2025-01-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)